Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

62P - Pyrrole-based carboxamides exhibit potent cytotoxic activities against epithelial cancer cell lines via targeting tubulin polymerization

Date

06 Oct 2021

Session

e-Posters

Presenters

Sergei Boichuk

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

S.V. Boichuk1, A. Galembikova2, F. Bikinieva3, P. Dunaev3, S. Zykova4, N. Igidov4

Author affiliations

  • 1 KSMU - Kazan State Medical University, 420012 - Kazan/RU
  • 2 KSMU - Kazan State Medical University, Kazan/RU
  • 3 KSMU - Kazan State Medical University, 420012 - ??????/RU
  • 4 Perm State Academy of Pharmacy, 310010 - Perm/RU
More

Abstract 62P

Background

Despite microtubule-targeting agents (MTAs) being known as the most potent anti-cancer drugs, they exhibit several serious limitations, including an acquired resistance after initiation of MTA-based therapy. This, in turn, represents a driving force to develop novel therapeutic agents effectively targeting microtubules.

Methods

Activities of pyrrole-based carboxamides (PBCs) were examined against a broad spectrum of epithelial cancer cell lines, including breast, lung, and prostate cancer. Cellular viability was assessed by MTS-based assay. Western blotting was used to examine cell cycle abnormalities (expression of cyclins A2, B1, Mdm2, pH3Ser10, etc.) and apoptotic markers (cleaved forms of caspase-3 and PARP). Cell cycle analysis was also examined by flow cytometry PI-based staining assay. Tubulin polymerization assay was used to examine PBC's ability to interfere with the microtubule's dynamical state.

Results

We found that PBCs exhibit potent cytotoxic activities against H1299 lung cancer, PC-3 prostate cancer, HCC1806, and MDA-MD-231 breast cancer cells lines and induced their apoptotic death in a time- and dose-dependent manner. Cell cycle analysis revealed the accumulation of cancer cells in the G2/M phase after PBCs treatment. Importantly, selective enhancement of pH3(Ser10)-positive cells revealed PBC’s ability to induce selective accumulation of cancer cells in the M-phase. This was due to their ability to inhibit tubulin polymerization, thereby illustrating their molecular mechanism of action.

Conclusions

Our data describe the novel MTAs that interfere with the microtubule's dynamic state and thereby provide anti-proliferative and pro-apoptotic activities against a broad spectrum of epithelial cancer cell lines.

Legal entity responsible for the study

The authors.

Funding

Russian Science Foundation (RSF) (grant no. 20-15-00001).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.